|
|
Post by mango on Sept 13, 2019 12:03:22 GMT -5
Triptans are serotonin receptor agonists. Claims 1. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of a triptan selected from sumatriptan, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan and pharmaceutically acceptable salts thereof. 2. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an aliphatic amino acid selected from the group consisting of alanine, glycine, leucine, isoleucine, norleucine and serine. 3. The dry powder inhaler of claim 2, wherein the aliphatic amino acid comprises 0.5% to 30% by weight of the pharmaceutical composition. 4. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an excipient. 5. The dry powder inhaler of claim 1, wherein the dry powder comprises microparticles, and 35% to 75% of the microparticles have an aerodynamic diameter of less than 5.8 µm. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises L-leucine. 7. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of sumatriptan or rizatriptan, and optionally, 0.5% to 30% leucine or isoleucine. 8. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is an amorphous powder. 9. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is a crystalline powder. 10. The dry powder inhaler of claim 1 or 7, wherein the rizatriptan is rizatripan benzoate. 11. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition, optionally, further comprises a pharmaceutically acceptable excipient. 12. The dry powder inhaler of claim 11, wherein the pharmaceutically acceptable excipient is a surfactant. 13. The dry powder inhaler of claim 12, wherein the surfactant is Polysorbate 80. 14. The dry powder inhaler of any of the preceding claims for oral administration of the dry powders for treating migraines by pulmonary delivery of the triptan. 15. The dry powder inhaler of claim 14 for use in combination with an additional active agent including, fluoxetidine or duloxetine. |
|
|
|
Post by peppy on Sept 13, 2019 12:07:49 GMT -5
Triptans are serotonin receptor agonists. Claims 1. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of a triptan selected from sumatriptan, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan and pharmaceutically acceptable salts thereof. 2. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an aliphatic amino acid selected from the group consisting of alanine, glycine, leucine, isoleucine, norleucine and serine. 3. The dry powder inhaler of claim 2, wherein the aliphatic amino acid comprises 0.5% to 30% by weight of the pharmaceutical composition. 4. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an excipient. 5. The dry powder inhaler of claim 1, wherein the dry powder comprises microparticles, and 35% to 75% of the microparticles have an aerodynamic diameter of less than 5.8 µm. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises L-leucine. 7. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of sumatriptan or rizatriptan, and optionally, 0.5% to 30% leucine or isoleucine. 8. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is an amorphous powder. 9. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is a crystalline powder. 10. The dry powder inhaler of claim 1 or 7, wherein the rizatriptan is rizatripan benzoate. 11. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition, optionally, further comprises a pharmaceutically acceptable excipient. 12. The dry powder inhaler of claim 11, wherein the pharmaceutically acceptable excipient is a surfactant. 13. The dry powder inhaler of claim 12, wherein the surfactant is Polysorbate 80. 14. The dry powder inhaler of any of the preceding claims for oral administration of the dry powders for treating migraines by pulmonary delivery of the triptan. 15. The dry powder inhaler of claim 14 for use in combination with an additional active agent including, fluoxetidine or duloxetine. oh, yippee, migrane. |
|
|
|
Post by mango on Sept 13, 2019 12:24:46 GMT -5
Claims 1. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of a triptan selected from sumatriptan, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan and pharmaceutically acceptable salts thereof. 2. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an aliphatic amino acid selected from the group consisting of alanine, glycine, leucine, isoleucine, norleucine and serine. 3. The dry powder inhaler of claim 2, wherein the aliphatic amino acid comprises 0.5% to 30% by weight of the pharmaceutical composition. 4. The dry powder inhaler of claim 1, wherein the pharmaceutical composition further comprises an excipient. 5. The dry powder inhaler of claim 1, wherein the dry powder comprises microparticles, and 35% to 75% of the microparticles have an aerodynamic diameter of less than 5.8 µm. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises L-leucine. 7. A dry powder inhaler comprising an orally inhalable pharmaceutical composition comprising a dry powder comprising 3,6-bis[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine or a salt thereof, 1-50 mg of sumatriptan or rizatriptan, and optionally, 0.5% to 30% leucine or isoleucine. 8. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is an amorphous powder. 9. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition is a crystalline powder. 10. The dry powder inhaler of claim 1 or 7, wherein the rizatriptan is rizatripan benzoate. 11. The dry powder inhaler of claim 1 or 7, wherein the pharmaceutical composition, optionally, further comprises a pharmaceutically acceptable excipient. 12. The dry powder inhaler of claim 11, wherein the pharmaceutically acceptable excipient is a surfactant. 13. The dry powder inhaler of claim 12, wherein the surfactant is Polysorbate 80. 14. The dry powder inhaler of any of the preceding claims for oral administration of the dry powders for treating migraines by pulmonary delivery of the triptan. 15. The dry powder inhaler of claim 14 for use in combination with an additional active agent including, fluoxetidine or duloxetine. oh, yippee, migrane. A new learning endeavor, yippee |
|
|
|
Post by mytakeonit on Sept 13, 2019 12:39:57 GMT -5
Revelation - peppy is only 99% #Nasty Women
But, that's mytakeonit
|
|
|
|
Post by uflawdog on Sept 13, 2019 13:37:36 GMT -5
This European Patent Office Application (EP3536368) isn't exactly new. It was filed in 2011. The U.S. version of it is US20170232001, which is still pending approval and which claims priority back to a 2007 patent application. So, if a patent issues from the U.S. patent application, it could expire in 2027, depending on whether its claims find support in the 2007 priority patent application.
|
|
|
|
Post by mango on Sept 17, 2019 17:49:45 GMT -5
New MannKind Granted Patent Published 9/17/2019 Heat-stable dry powder pharmaceutical compositions and methodsAbstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution. Assignee: MannKind Corporation Inventors: Karine Fabio, Joseph J. Guarneri, Kieran Curley, Marshall L. Grant, Andrea Leone-Bay patents.justia.com/patent/10413513 |
|
|
|
Post by apidistra on Sept 17, 2019 18:26:32 GMT -5
High humidity and temperatures.. As in Brazil and India...?
|
|
|
|
Post by mango on Sept 17, 2019 18:36:59 GMT -5
High humidity and temperatures.. As in Brazil and India...? Oxytocin |
|
|
|
Post by brotherm1 on Sept 17, 2019 20:30:31 GMT -5
Thanks for your dedicated patent service over the years here Mango. Much appreciated. I guess that Torey Pines Institute disappeared to somewhere. Wasn’t the Gates’ foundation helping with this to some degree? Were we not also contracted for a big milestone payment for this? It’s been so long this subject appeared, my memory fails me.
|
|
|
|
Post by mnholdem on Sept 18, 2019 4:03:52 GMT -5
It appears that the patent registration in Europe for the collaboration between MannKind and Torrey Pines for pain management was withdrawn last month. The decision was published in March 2019 and the IPO database was updated yesterday Sept 17. register.epo.org/application?number=EP12784825&tab=mainExcerpt; EP2776053 - METHODS AND COMPOSITIONS FOR TREATING PAIN [Right-click to bookmark this link] Status The application is deemed to be withdrawn Status updated on 08.02.2019 Database last updated on 17.09.2019 Most recent event Application deemed to be withdrawn. Published on 13.03.2019 [2019/11] |
|
|
|
Post by mnholdem on Sept 18, 2019 4:17:32 GMT -5
|
|
|
|
Post by peppy on Sept 18, 2019 6:12:13 GMT -5
|
|
|
|
Post by goyocafe on Sept 18, 2019 6:31:35 GMT -5
SMH, roll my eyes, fill my pants with ants. WTF?! |
|
|
|
Post by mango on Sept 18, 2019 6:42:15 GMT -5
Thanks for your dedicated patent service over the years here Mango. Much appreciated. I guess that Torey Pines Institute disappeared to somewhere. Wasn’t the Gates’ foundation helping with this to some degree? Were we not also contracted for a big milestone payment for this? It’s been so long this subject appeared, my memory fails me. The Mintaka Foundation was working with MannKind on oxytocin. Maybe one day... www.mintakafoundation.org/our-projects/maternal-health/Robin Offord also did a pitch presentation with the economics and development costs. I’ve posted the video before but can’t find it atm. |
|
|
|
Post by mnholdem on Sept 18, 2019 7:18:36 GMT -5
I remember reading quite a bit about that group. European-based, as I recall. The issue with them was that they appeared to be having difficulty getting funded. Although collaborations are a good thing, having a partner that can bankroll product development is preferable, IMO.  |
|
